Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15792MR)

This product GTTS-WQ15792MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15792MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6906MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ11128MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ10564MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5178MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ10388MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ11808MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ12164MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ8746MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuPRO-140
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW